Frank Kalkbrenner – Startup Investor Profile

Frank Kalkbrenner is the Global Head of the Boehringer Ingelheim Venture Fund, involved in several investments of the fund. With a background in Medicine and Pharmacology, his investment focus areas include German High-Tech companies, Health Care, Biotech, and Digital Health startups in seed or series A phase. He has been engaged in investments worldwide, with specific focus on North America and Europe. Frank’s previous investments include companies like Abexxa Biologics, Amal Therapeutics, and STAT Dx. He prioritizes collaborative approaches with a track record of strategic investments in therapeutics and digital health innovations.

Location:

Country: Germany

Investment Regions: EU, MENA

Investment Stages: pre-seed, seed

Website: https://www.boehringer-ingelheim-venture.com/team.php

AI Reasoning: Search results show Frank Kalkbrenner was involved in Amal Therapeutics Series B announced 12 November 2018 (investor: Boehringer Ingelheim Venture Fund). I found no evidence of more recent individual investment activity by Frank Kalkbrenner or BIVF involving him as lead since then. The most recent cited investments (Amal, Abexxa, STAT Dx) have earlier dates; therefore the last known investment activity is well over 12 months ago (more than 7 years). Hence classify as low-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.